MONTREAL, April 08, 2025 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is proud to announce the award of a grant under the Mining Exploration Support Program for Critical and Strategic Minerals of the Ministry of Natural Resources and Forests (“MRNF”) for its Crevier 2 niobium & tantalum project, which is the southern and northern extension of the original Crevier project already identified by a resource estimate (collectively, the “Crevier Project”). The Cre ...

Financial Performance - The company incurred net losses from continuing operations of $7.2 million for the year ending December 31, 2024, compared to $6.1 million for 2023, reflecting a 17% increase in losses [132]. - Total net sales decreased by $0.7 million, or 6%, to $9.8 million for the year ended December 31, 2024, down from $10.5 million in 2023 [141]. - Product revenue, net, from eyecare products increased by $0.6 million to $9.7 million for the year ended December 31, 2024, primarily due to increased sales of Avenova Spray [145]. - Operating expenses increased by 21% to $12.3 million for the year ended December 31, 2024, compared to $10.2 million in 2023 [141]. - The company recorded a loss on divestiture of subsidiary amounting to $865,000, reflecting the impact of recent strategic changes [141]. - Cash and cash equivalents decreased to $430 thousand as of December 31, 2024, compared to $2.9 million as of December 31, 2023 [156]. - Net cash used in operating activities from continuing operations was $5.2 million for the year ended December 31, 2024, compared to $4.3 million for the year ended December 31, 2023 [160][161]. - Net cash provided by financing activities from continuing operations was $1.5 million for the year ended December 31, 2024, compared to $1.9 million for the year ended December 31, 2023 [163][164]. Asset and Liability Management - The accumulated deficit as of December 31, 2024, was $183.5 million, with total current assets of $1.9 million and total assets of $3.4 million [132]. - As of December 31, 2024, the company had net operating loss carryforwards of $153.7 million for federal income tax purposes [166]. Strategic Changes - The company completed the Avenova Asset Sale on January 17, 2025, receiving net proceeds of approximately $10.5 million, significantly reducing its revenue-generating assets [132]. - Following the Wound Care Divestiture on January 8, 2025, the company received net proceeds of $0.5 million, further diminishing its operational scope [132]. - The company anticipates fulfilling remaining contractual obligations for wound care products by the end of Q2 2025 [129]. - The company is exploring strategic alternatives, including potential dissolution, which is subject to stockholder approval [133]. - The company is exploring strategic alternatives, including a potential dissolution, subject to stockholder approval [159]. Expense Management - Cost of goods sold decreased by $1.1 million, or 25%, to $3.3 million for the year ended December 31, 2024, from $4.4 million for the year ended December 31, 2023 [147]. - Sales and marketing expenses decreased by $0.7 million, or 14%, to $4.0 million for the year ended December 31, 2024, from $4.7 million for the year ended December 31, 2023 [148]. - General and administrative expenses increased by $1.9 million, or 35%, to $7.4 million for the year ended December 31, 2024, from $5.4 million for the year ended December 31, 2023 [149].

MONTRÉAL, March 26, 2025 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce the appointment of Mr. Laurence Farmer to the Board of Directors, in replacement of Mr. Mathieu Savard who has resigned as a director of the Company on March 25, 2025. The Company wishes to thank Mr. Savard for his work and dedication over the years and wishes him well in his future endeavors as President, CEO and Director of Vior Inc. Since July 2022, Laurence Farme ...

MONTRÉAL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is proud to announce that it has intercepted titanium in several of the surface drill holes carried out in Zone 1, on the Foothills Property, located on the lands of the Séminaire de Québec. The Company had filed an application for authorization for impact projects with the Ministry of Natural Resources with the aim of carrying out a drilling campaign as soon as authorization is received. B ...

Company Overview - NioBay Metals Inc is focused on exploration, development, and use of critical green metals with an Environmentally, Sustainable, Governance, and Indigenous (ESGI) focus [4] - The company holds a 100% interest in the James Bay Niobium Project located 45 km south of Moosonee, Ontario [4] - NioBay also holds a 72.5% interest in the Crevier Niobium and Tantalum project in Québec and has an option to acquire an 80% interest in the Foothills titanium-phosphate project in Quebec [4] Metallurgical Testing Results - Successful production of Ammonium Niobium Oxalate (ANO) was achieved through a reliable flowsheet incorporating hydrofluoric acid leaching, solvent extraction using 1-octanol, and precipitation with ammonium hydroxide [3] - Hydrofluoric acid leaching consistently achieved niobium dissolution in excess of 95% across a range of acid dosages [5] - A reverse precipitation test produced a residue assaying at 59.4% Nb with very low levels of impurity co-precipitation [5] Strategic Implications - The metallurgical tests reveal an opportunity to target markets demanding high-purity niobium, beyond the company's primary focus on ferroniobium production for the steel mill market [4] - The James Bay Niobium Project's mineralization can be processed to produce high-purity niobium, as confirmed by SGS results [4] Industry Context - Niobium is a naturally occurring metal that enhances properties and functionalities in materials used across Mobility, Structural, and Energy sectors [6] - When added to materials like steel, glass, and aluminum castings, niobium improves efficiency, lowers environmental impacts, and delivers benefits such as better performance, improved safety, and increased value [6]

Investors might want to bet on NovaBay Pharmaceuticals, Inc. (NBY) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The ...

MONTRÉAL, Dec. 19, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is proud to present its year-end report. Foothills (Titanium Exploration Project)The Foothills project consists of a series of mining claims located near Saint-Urbain, which has a long history as a mining sector. Following the option agreement with Vior Inc., NioBay conducted an exploration campaign on the claims covered by the option from the end of May to August. Excellent values were obt ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 68-045 ...

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jody Cain - LHA, Investor Relations Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Destiny Buch - Ladenburg Thalman Edward Woo - Ascendiant Capital Operator Good day, and welcome to the NovaBay Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only m ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 68-0454536 ...